Safety of Brexanolone in Adults with Postpartum Depression: Postmarketing Surveillance Data

Autor: Svetlana Garafola, Elizabeth Shiferaw, Vikram Dev

Publikováno v: Drugs - Real World Outcomes, Vol 10, Iss 3, Pp 351-356 (2023)

Abstract Background Brexanolone is currently the only medication approved by the US FDA for the treatment of postpartum depression (PPD) in patients ≥15 years. Brexanolone is available commercially only through a restricted program (ZULRESSO® Risk

Externí odkaz: https://doaj.org/article/1ff14917abcb4f258f81fc789b920cfe

Lanthanum carbonate: safety data after 10years

Autor: Alastair J. Hutchison, John Brian Copley, Rosamund Wilson, Svetlana Garafola

Publikováno v: Hutchison, A 2016, ' Lanthanum carbonate: safety data after 10years ', Nephrology . https://doi.org/10.1111/nep.12864
Nephrology (Carlton, Vic.)

Despite 10 years of post‐marketing safety monitoring of the phosphate binder lanthanum carbonate, concerns about aluminium‐like accumulation and toxicity persist. Here, we present a concise overview of the safety profile of lanthanum carbonate an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::406eff9d48e19b97e7e9a44c1ffe527b
https://pure.manchester.ac.uk/ws/files/49527663/Hutchison_et_al_2016_Nephrology.pdf

Lanthanum carbonate: safety data after 10 years.

Autor: Hutchison, Alastair J¹ alastair.hutchison@cmft.nhs.uk, Wilson, Rosamund J², Garafola, Svetlana³, Copley, John Brian⁴

Publikováno v: Nephrology. Dec2016, Vol. 21 Issue 12, p987-994. 8p.

Studies from Sage Therapeutics Inc. in the Area of Postpartum Depression Described (Safety of Brexanolone in Adults with Postpartum Depression: Postmarketing Surveillance Data).

Publikováno v: Women's Health Weekly; 9/26/2023, p1572-1572, 1p